Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

AbbVie CEO Robert Michael will soon add the role of board chairman to his résumé. Michael, who became CEO of the North Chicago-based pharmaceutical giant last summer, will assume duties as ...

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

Injectable Drug Delivery MarketThe global injectable drug delivery market is estimated to be valued at USD 49.44 billion in ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...

SAE Media Group's 15th Annual Pre-Filled Syringes and Injectable Drug Devices ... afternoon topic streams as detailed below: Novel Drug Products and Large Volume Delivery Sustainability for ...

With healthcare rapidly evolving through digital transformation, the demand for smarter, more efficient solutions is rising, ...

Its syringe products include syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for ...